New Data Supports Correlation Between Secretoneurin and Cardiovascular Disease

Prognostic Value of Secretoneurin in Patients with Acute Respiratory Failure,” published in Clinical Chemistry, and “Prognostic Value of Secretoneurin in Critically Ill Patients With Infection,” published in Critical Care Medicine, both document that elevated levels of secretoneurin in these patient groups are linked to increased cardiovascular mortality.

Taking into account existing studies, secretoneurin appears to be a biomarker that provides strong and complementary prognostic information to established risk indices in critically ill patients with infections. Accordingly, it shows potential as a prognostic biomarker across different populations with myocardial dysfunction.

Secretoneurin is therefore generating significant interest as a potential missing link in the assessment and management of the 30 million patients with arrhythmia. An editorial headline in the Journal of the American College of Cardiology (JACC) previously asked: “Will Secretoneurin be the next big thing?”, referring to its potential role in complementing troponin and BNP as a third key frontline test in patients with cardiovascular disease.

According to CardiNor CEO Dag Christiansen, this is welcome news: “An increasing body of evidence points to the value of secretoneurin as a cardiovascular risk marker, and we are continuing according to plan with our efforts to develop a frontline ELISA assay.”

CardiNor aims to develop a blood-based assay for secretoneurin. A European patent for SN in cardiovascular disease was recently granted and, together with the earlier US patent, gives CardiNor a strong IP position.

Cardiovascular disease continues to be the leading cause of morbidity and mortality worldwide. It is estimated that approximately 42 million people will have heart failure by 2018. Currently, the cost to US society alone exceeds USD 31 billion.